Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.

[coats disease]

To compare intraocular vascular endothelial growth factor (VEGF ) level in patients with and without Coats ' disease , and to report a case of Coats ' disease that responded to intravitreal injection of bevacizumab .Intraocular fluid was obtained from four eyes with Coats ' disease (subretinal fluid in three eyes and aqueous in one eye ) and from five eyes with rhegmatogenous retinal detachment (subretinal fluid in four eyes and vitreous in one eye ). Intraocular VEGF level was compared between these two groups . In one eye with stage 2 B Coats ' disease , macular edema , visual acuity , and intraocular VEGF level were compared before and after intravitreal injection of bevacizumab .Mean intraocular VEGF level in eyes with Coats ' disease was 2 ,394 .5 pg /ml , compared to 15 .3 pg /ml in eyes with rhegmagenous retinal detachment . In the eye with stage 2 B Coats ' disease , macular edema was reduced after bevacizumab injection , and the visual acuity improved from 0 .05 to 0 .2 . Intraocular VEGF level decreased from 1247 pg /ml to 20 .4 pg /ml 1 month after the injection .Coats ' disease is associated with increased intraocular VEGF level . Bevacizumab may be a valuable adjunctive treatment for Coats ' disease .

Diseases
Validation

Diseases presenting "increased intraocular vegf level" symptom

coats disease

You can validate or delete this automatically detected symptom